Back to results
US 2021/0198199 A1Published application
Pharmaceutical composition for treating fibrosis
AssigneesLTT Bio-Pharma Co., Ltd., Musashino University
InventorsTohru MIZUSHIMA, Ken-ichiro TANAKA
Life of this patent
Estimating the term…
Abstract
To provide a novel therapeutic agent for fibrosis that induces selective cell death of lung fibroblasts and suppresses lung fibrosis without injuring alvocar epithelial cells. A pharmaceutical composition for treating fibrosis, the pharmaceutical composition comprising a compound of formula (I) or formula (II): wherein in formula (I), R1 represents a C1-4 alkyl group optionally substituted with a halogen atom, and l represents an integer of 3 to 6; and in formula (II), n represents an integer of 8 to 12, or a pharmaceutically acceptable salt thereof or a solvate of the compound or the salt thereof.
Claims23
1:
- A pharmaceutical composition for treating fibrosis, the pharmaceutical composition comprising a compound of formula (I) or formula (II):
- wherein in formula (I), R1 represents a C1-4 alkyl group optionally substituted with a halogen atom, and 1 represents an integer of 3 to 6;
- and in formula (II), n represents an integer of 8 to 12,
- or a pharmaceutically acceptable salt thereof or a solvate of the compound or the salt thereof.
1 more element
2:
- The pharmaceutical composition according to claim 1, comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof or a solvate of the compound or the salt thereof.
3:
- The pharmaceutical composition according to claim 2, wherein in formula (I), 1 is 4 or 5, and R1 is a methyl group, an ethyl group or a trifluoromethyl group.
4:
- The pharmaceutical composition according to claim 2 or 3, wherein in formula (I), 1 is 5, and R1 is a methyl group or an ethyl group.
5:
- The pharmaceutical composition according to claim 1, comprising a compound of formula (II), or a pharmaceutically acceptable salt thereof or a solvate of the compound or the salt thereof.
6:
- The pharmaceutical composition according to claim 5, wherein in formula (II), n is 10.
7-8. (canceled)
9:
- The pharmaceutical composition according to claim 1, wherein the pharmaceutical composition is formulated for airway administration.
10:
- The pharmaceutical composition according to claim 1, wherein the pharmaceutical composition is formulated for oral administration.
11:
- The pharmaceutical composition according to claim 1, wherein the pharmaceutical composition is formulated for transvenous administration.
12:
- A compound of formula (I) or formula (II):
- wherein in formula (I), R1 represents a C1-4 alkyl group optionally substituted with a halogen atom, and 1 represents an integer of 3 to 6;
- and in formula (II), n represents an integer of 8 to 12,
- or a pharmaceutically acceptable salt thereof or a solvate of the compound or the salt thereof, for use in treating fibrosis, the compound.
1 more element
(canceled)
14:
- A method for treating fibrosis, the method comprising administering to a subject in need thereof an effective amount of a compound of formula (I) or formula (II):
- wherein in formula (I), R1 represents a C1-4 alkyl group optionally substituted with a halogen atom, and 1 represents an integer of 3 to 6;
- and in formula (II), n represents an integer of 8 to 12,
- or a pharmaceutically acceptable salt thereof or a solvate of the compound or the salt thereof.
1 more element
15:
- The method according to claim 14, comprising administering a corn pound of formula (I), or a pharmaceutically acceptable salt thereof or a solvate of the compound or the salt thereof.
16:
- The method according to claim 15, wherein in formula (I), 1 is 4 or 5, and R1 is a methyl group, an ethyl group or a trifluoromethyl group.
17:
- The method according to claim 15, wherein in formula (I), 1 is 5, and R1 is a methyl group or an ethyl group.
18:
- The method according to claim 14, comprising administering a compound of formula (II), or a pharmaceutically acceptable salt thereof or a solvate of the compound or the salt thereof.
19:
- The method according to claim 18, wherein in formula (II), n is 10.
20:
- The method according to claim 14, wherein the fibrosis is a pulmonary fibrosis.
21:
- The method according to claim 20, wherein the pulmonary fibrosis is idiopathic pulmonary fibrosis.
22:
- The method according to claim 14, wherein said compound of formula (I) or formula (II) is administered by airway administration.
23:
- The method according to claim 14, wherein said compound of formula (I) or formula (II) is administered by oral administration.
24:
- The method according to claim 14, wherein said compound of formula (I) or formula (II) is administered by transvenous administration.
Dependencies are inferred from the claim text.